The simplicity of enzyme-linked immunosorbent assays (ELISAs) has made them a popular assay for detecting and quantifying proteins, antibodies, peptides, and more.
However, traditional ELISAs suffer from low sensitivity, meaning some biomarkers are difficult to detect, and others are completely undetectable using this method.
Join this webinar to discover how switching from ELISAs to an ultrasensitive biomarker detection platform increases assay sensitivity by up to 1,000-fold, allowing you to detect the previously undetectable.
In this webinar, you will discover:
- Why traditional ELISAs are limited;
- Ways to improve the sensitivity, throughput, and reliability of immunoassays
- How making the switch from ELISAs to an ultrasensitive assay platform is a straightforward process
- The technology behind the ultrasensitive Single Molecule Counting (SMC®) technology platform
- How researchers are applying this technology to reliably detect the previously undetectable
For Research Use Only. Not For Use In Diagnostic Procedures.
Speakers
Craig Lanio
Merck
Senior Scientific Sales Manager
Craig was a Field Application Scientist with the Immunoassay Platform Solutions team for almost 15 years. Prior to coming to Merck, he was a scientist with multiple biopharma companies where he participated in every stage of the drug discovery process, including analytical method development and assay validation. Craig is currently Senior Scientific Sales Manager with the Global Strategic Accounts Team at Merck.
Protein biology
- Protein quantitation
Durata:27min
Lingua:English
Sessione 1:tenuto November 16, 2021
Per continuare a leggere, autenticati o crea un account.
Non hai un Account?